Rheumatoid arthritis

RA · Immunology · 8 drugs · 4 indications

Autoimmune joint inflammation.
Competitive Landscape (8 drugs)
DrugCompanyMechanismModalityRouteStage
CimziaUCBTNF inhibitorAntibodySCAPPROVED
OlumiantLLYJAK inhibitorSmall moleculeORALAPPROVED
Actemra/RoActemraROG.SWIL-6 receptor antagonistAntibodyIV/SCAPPROVED
Rituxan/MabTheraROG.SWCD20 antagonistAntibodyIVAPPROVED
RinvoqABBVJAK inhibitorSmall moleculeORALAPPROVED
HumiraABBVTNF inhibitorAntibodySCAPPROVED
EnbrelAMGNTNF inhibitor (fusion protein)Fusion proteinSCAPPROVED
KevzaraREGNAnti-IL-6R (Recycling)Monoclonal antibodySCAPPROVED
Indications (4)
Rheumatoid arthritis (moderate-to-severe, TNF-IR)
Kevzara APPROVED
Moderate-severe rheumatoid arthritis
Rinvoq APPROVEDHumira APPROVED
Rheumatoid arthritis
Cimzia APPROVEDOlumiant APPROVEDActemra/RoActemra APPROVEDEnbrel APPROVED
RA
Rituxan/MabThera APPROVED
Upcoming Catalysts
Rinvoq - Vitiligo - FDA ApprovalREGULATORY
ABBV2026
Rinvoq - GCA - FDA ApprovalREGULATORY
ABBV2026
Rinvoq - Alopecia Areata - Ph3 - Data (UP-AA)CLINICAL
ABBV2026
Rinvoq - HS - Ph3 - DataCLINICAL
ABBV2026
Rinvoq - SLE - Ph3 - DataCLINICAL
ABBV2026
Data from Supabase · Updated 2026-03-24